SCHEMBL6866217

SCHEMBL6866217

CCCCCC(=O)NS(=O)(=O)c1ccccc1NC(=O)c1ccc(C#Cc2ccccc2)c(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 5/20 0.41
PLK3 Q9H4B4 4/20 0.41
PTPN1 P18031 1/20 0.38
PTGES O14684 1/20 0.37
PDGFRB P09619 1/20 0.37
KDR P35968 1/20 0.37
FFAR1 O14842 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
CNR2 P34972 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
ALKBH2 Q6NS38 1/20 0.35
ALKBH3 Q96Q83 1/20 0.35
FTO Q9C0B1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6864872 0.92 PTGES (0.37) PLK1PLK3PTGESPDGFRBKDR
SCHEMBL6860325 0.89 SLC16A3 (0.42) PLK1PLK3PTGESPDGFRBKDR
SCHEMBL6860340 0.87 PTGES (0.36) PLK1PLK3PTGESPDGFRBKDR
SCHEMBL7048492 0.86 PTGES (0.50) PLK1PLK3PTGESSMN1; SMN2
SCHEMBL7051034 0.85 PTGES (0.49) PLK1PLK3PTGESSMN1; SMN2
SCHEMBL6867142 0.80 CA2 (0.52) PTGESFFAR1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6866219 0.80 RXFP1 (0.43) PLK1PLK3PTPN1SMN1; SMN2ALDH1A1
SCHEMBL7080234 0.78 MMP2 (0.43) PLK1PLK3PTGESFFAR1ALDH1A1
SCHEMBL14106418 0.77 PLK1 (0.44) PLK1PLK3PTPN1SMN1; SMN2ALDH1A1
SCHEMBL7083554 0.77 MMP2 (0.47) PLK1PLK3PTGESFFAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812252-B2 ACYLSULFONAMIDE DERIVATIVES CONTAINING FLUOROSUBSTITUTEDPHENYLETHYNYL GROUP HAVING A HYPOGLYCEMIC EFFECT AND FREE OF THE SIDE EFFECT AJINOMOTO CO., INC. (JP) 2004-11-02 US disclosed
US-20030191323-A1 Hypoglycemic agent AJINOMOTO CO., INC. (JP) 2003-10-09 US disclosed
US-20030181764-A1 Acylsulfonamide derivatives AJINOMOTO CO. INC (JP) 2003-09-25 US disclosed
EP-1316548-A1 ACYLSULFONAMIDE DERIVATIVES Ajinomoto Co., Inc. (JP) 2003-06-04 EP disclosed
EP-1300142-A1 HYPOGLYCEMICS Ajinomoto Co., Inc. (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181764-A1 Acylsulfonamide derivatives DPP4, SLC5A2, GLP1R PLK1 4519/4885PLK3 1664/4885PTPN1 1289/4885
US-20030191323-A1 Hypoglycemic agent GPR119, IAPP, SLC5A2 PLK1 4638/4885PLK3 3062/4885PTPN1 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.